Takura is happy to strengthen its core team with Gunnar Forssell who will join towards the end of August as Executive Vice President Strategic Planning. Gunnar will also become the executive chairman of Takura’s immuno-onkology company CuraCell. Gunnar has extensive experience from senior positions in the pharmaceutical industry globally. His most recent job was as Executive Director […]
Om Maria Rankka
Författaren har inte skrivit något ännu.Meanwhile lets just say that we are proud Maria Rankka contributed a whooping 3 entries.
Inlägg av Maria Rankka
Takura’s executive chairman Per Båtelson presented the group on Stockholm Corporate Finance Financial Hearing today. The presentation and QA is 30 minutes and gives a high level overview of the group.
Takura has acquired all shares in clinical stage immuno-oncology company Polybiocept GmbH (PBC). Takura was already a minority owner in the company which owns a patent portfolio for TIL (tumor infiltrating lymphocytes) therapy. Immunotherapy is one of the fastest growing segments in the pharmaceutical industry and has the potential to revolutionize cancer care. PBC has […]
A Biocell Portfolio Development company that commercializes advanced cell therapy research in order to accelerate the development within regenerative medicine and make groundbreaking treatments more accessible and affordable.
- Gunnar Forssell, former strategy lead at Merck, joins Takura 30 juni, 2021
- TAKURA presents at Financial Hearings 23 mars, 2021
- Takura acquires Polybiocept GmbH 14 juli, 2020
- Takura joins forces with Abu Dhabi 26 september, 2019